MAZE
Maze Therapeutics, Inc. NASDAQ Listed Jan 31, 2025$25.68
+3.38%
vs $24.84
Mkt Cap $1.4B
52w Low $9.83
36.2% of range
52w High $53.65
50d MA $25.78
200d MA $33.81
P/E (TTM)
-8.4x
EV/EBITDA
—
P/B
3.1x
Debt/Equity
0.1x
ROE
-36.9%
P/FCF
-9.8x
RSI (14)
45.50
ATR (14)
$1.26
Beta
5.16
50d MA
$25.78
200d MA
$33.81
Avg Volume
526.4K
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
171 Oyster Point Blvd · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | BMO | — | — | — | 25.78 | +0.9% | +4.6% | -2.0% | -3.3% | -4.1% | -0.2% | — |
| May 12, 2026 | BMO | -0.58 | -0.45 | +22.0% | 25.52 | +0.1% | +1.0% | +4.6% | -2.0% | -3.3% | -4.1% | — |
| Mar 25, 2026 | BMO | -0.73 | -0.65 | +11.0% | 31.73 | -2.0% | -0.1% | -4.2% | -4.5% | +2.9% | -2.7% | — |
| Nov 6, 2025 | BMO | -0.74 | -0.66 | +10.8% | 29.63 | +0.8% | -3.5% | +6.6% | +5.8% | +0.9% | -2.2% | — |
| Aug 12, 2025 | BMO | -0.79 | -0.77 | +2.5% | 13.74 | +1.9% | -1.0% | -1.8% | +1.1% | -1.1% | +0.7% | — |
| May 14, 2025 | BMO | -0.76 | -1.15 | -51.3% | 9.06 | -2.5% | +2.1% | +0.0% | +4.9% | +4.2% | +4.1% | — |
| Mar 31, 2025 | BMO | 0.45 | -18.32 | -4171.1% | 11.01 | -2.8% | -10.1% | +4.7% | -10.1% | -2.7% | -1.7% | — |
| Sep 30, 2024 | BMO | — | -0.57 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2024 | BMO | — | 3.18 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2024 | BMO | — | -0.74 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | BMO | — | -0.61 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | BMO | — | -0.57 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 14 | Truist | Maintains | Buy → Buy | — | $27.42 | $27.66 | +0.9% | +0.9% | -3.0% | +0.1% | +4.5% | -4.5% |
| Mar 31 | JP Morgan | Maintains | Overweight → Overweight | — | $29.01 | $29.50 | +1.7% | +2.9% | -2.7% | -1.2% | +1.0% | -2.3% |
| Mar 25 | BTIG | Maintains | Buy → Buy | — | $49.00 | $40.00 | -18.4% | -35.2% | -0.1% | -4.2% | -4.5% | +2.9% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.00 | $40.00 | -18.4% | -35.2% | -0.1% | -4.2% | -4.5% | +2.9% |
| Mar 16 | Wedbush | Maintains | Outperform → Outperform | — | $50.21 | $50.96 | +1.5% | +2.1% | -1.7% | -3.8% | +2.0% | -2.8% |
| Mar 9 | BTIG | Maintains | Buy → Buy | — | $44.83 | $44.00 | -1.9% | +0.5% | +13.3% | -1.2% | +2.8% | -3.1% |
| Mar 4 | Guggenheim | Maintains | Buy → Buy | — | $44.18 | $46.59 | +5.5% | +5.2% | -2.5% | -1.0% | +0.5% | +13.3% |
| Jan 16 | BTIG | Maintains | Buy → Buy | — | $39.81 | $39.84 | +0.1% | +2.4% | +8.8% | -1.4% | +5.7% | -4.2% |
| Dec 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.27 | $37.89 | +1.7% | +11.3% | +2.7% | -2.1% | -0.6% | -1.7% |
| Nov 7 | Wedbush | Maintains | Outperform → Outperform | — | $29.63 | $29.87 | +0.8% | -3.5% | +6.6% | +5.8% | +0.9% | -2.2% |
| Sep 29 | JP Morgan | Maintains | Overweight → Overweight | — | $27.00 | $27.05 | +0.2% | -6.7% | +2.9% | -0.5% | +2.7% | +2.3% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.50 | $23.64 | +0.6% | -0.1% | -2.3% | +3.2% | +5.1% | +5.2% |
| Sep 15 | Guggenheim | Maintains | Buy → Buy | — | $23.30 | $23.33 | +0.1% | -0.2% | +0.9% | +0.2% | -0.1% | -2.3% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.80 | $24.88 | +0.3% | -6.0% | -0.2% | +0.9% | +0.2% | -0.1% |
| Sep 12 | BTIG | Maintains | Buy → Buy | — | $24.80 | $24.88 | +0.3% | -6.0% | -0.2% | +0.9% | +0.2% | -0.1% |
| Sep 11 | BTIG | Maintains | Buy → Buy | — | $16.02 | $21.10 | +31.7% | +54.8% | -6.0% | -0.2% | +0.9% | +0.2% |
| Apr 2 | Guggenheim | Maintains | Buy → Buy | — | $9.90 | $9.90 | +0.0% | +4.7% | -10.1% | -2.7% | -1.7% | -15.1% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Coloma Jason V | Chief Executive Officer | Sell | 553 | $26.24 | $15K | 27,970 | +2.17% | -1.13% |
| Jun 1, 2026 | Coloma Jason V | Chief Executive Officer | Sell | 6,090 | $26.20 | $160K | 344,897 | +2.17% | -1.13% |
| Jun 1, 2026 | Bernstein Harold | President, R&D & CMO | Sell | 1,600 | $26.36 | $42K | — | +2.17% | -1.13% |
| Jun 1, 2026 | Bernstein Harold | President, R&D & CMO | Sell | 13,253 | $25.57 | $339K | 1,600 | +2.17% | -1.13% |
| May 29, 2026 | Dandekar Atul | CSBO | Sell | 7,500 | $26.34 | $198K | 24,808 | +2.35% | +1.48% |
| May 26, 2026 | Coloma Jason V | Chief Executive Officer | Sell | 25,582 | $26.02 | $666K | 350,987 | +1.34% | +2.35% |
| May 22, 2026 | Coloma Jason V | Chief Executive Officer | Sell | 2,478 | $26.00 | $64K | 28,523 | +1.34% | +2.35% |
| May 22, 2026 | Coloma Jason V | Chief Executive Officer | Sell | 4,504 | $26.00 | $117K | 376,569 | +1.34% | +2.35% |
| May 15, 2026 | Coloma Jason V | Chief Executive Officer | Sell | 116 | $26.00 | $3K | 31,001 | -0.16% | +2.21% |
| May 15, 2026 | Coloma Jason V | Chief Executive Officer | Sell | 1,822 | $26.00 | $47K | 381,073 | -0.16% | +2.21% |
| May 14, 2026 | Bernstein Harold | President, R&D & CMO | Sell | 15,000 | $26.22 | $393K | — | -0.16% | +2.21% |
| Apr 29, 2026 | Dandekar Atul | CSBO | Sell | 7,500 | $25.37 | $190K | 10,503 | -0.88% | +2.20% |
8-K
Maze Therapeutics, Inc. -- 8-K Filing
Jun 10
8-K · 2.02
!! High
Maze Therapeutics, Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 8.01
!! High
Maze Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Maze Therapeutics is conducting a public offering of shares at $23.50 per share and pre-funded warrants at $23.499, providing investors with immediate equity exposure and minimal-cost warrant exercise options.
Apr 22
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Kumar's departure as CEO of BridgeBio Oncology signals potential leadership instability at the oncology subsidiary, which could impact clinical trial progress and investor confidence in the parent company's pipeline.
Mar 25
8-K · 1.01
!! High
Maze Therapeutics, Inc. -- 8-K 1.01: Material Agreement
Maze Therapeutics secured $40 million in initial term loan funding from Hercules Capital, providing capital for operations and development while obligating the company to repay debt.
Feb 4
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Janus Henderson Group Plc | 2,858,876 | $85M | New | Mar 2026 |
| 2 | Vr Adviser, Llc | 1,548,569 | $64M | Added | Dec 2025 |
| 3 | Alphabet Inc. | 1,388,583 | $58M | Reduced | Dec 2025 |
| 4 | Vanguard Capital Management Llc | 1,435,656 | $43M | New | Mar 2026 |
| 5 | Fmr Llc | 864,214 | $26M | Added | Mar 2026 |
| 6 | Citadel Advisors Llc | 775,714 | $23M | Added | Mar 2026 |
| 7 | Morgan Stanley | 516,172 | $21M | Added | Dec 2025 |
| 8 | Woodline Partners Lp | 650,229 | $19M | Reduced | Mar 2026 |
| 9 | Washington University | 280,802 | $12M | Added | Dec 2025 |
| 10 | Farallon Capital Management Llc | 373,000 | $11M | New | Mar 2026 |
| 11 | Marshall Wace, Llp | 310,639 | $9M | Reduced | Mar 2026 |
| 12 | Mass General Brigham, Inc | 239,994 | $7M | — | Mar 2026 |
| 13 | Aberdeen Group Plc | 226,227 | $7M | New | Mar 2026 |
| 14 | Northern Trust Corp | 211,382 | $6M | Added | Mar 2026 |
| 15 | Vanguard Portfolio Management Llc | 195,542 | $6M | New | Mar 2026 |
| 16 | Bank Of America Corp /de/ | 195,084 | $6M | Added | Mar 2026 |
| 17 | Ensign Peak Advisors, Inc | 185,794 | $6M | — | Mar 2026 |
| 18 | Foresite Capital Management Iv, Llc | 156,901 | $5M | Reduced | Mar 2026 |
| 19 | Qube Research & Technologies Ltd | 134,950 | $4M | New | Mar 2026 |
| 20 | Foresite Capital Management V, Llc | 86,291 | $4M | — | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.42B
Enterprise Value
$761.7M
P/E (TTM)
-8.42x
Forward P/E
—
PEG Ratio
0.00x
P/B
3.11x
P/S
—
P/FCF
-9.79x
EV/EBITDA
—
Shares Out
43.0M
Financials (TTM)
Revenue
$0
Net Income
-$131.1M
EBITDA
-$140.5M
Free Cash Flow
-$112.7M
Op Cash Flow
-$111.9M
EPS Basic
$-3.05
EPS Diluted
$-3.05
EPS Forward
$-2.84
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$397.1M
Total Liab.
$42.2M
Total Equity
$355.0M
Cash
$341.9M
LT Debt
$0
Book Value/Sh
$8.26
Debt/Equity
0.07x
Current Ratio
15.50
Quick Ratio
15.50
Returns & Growth
ROE
-36.9%
ROA
-33.0%
ROIC
-37.7%
Rev Growth YoY
-100.0%
EPS Growth YoY
-4020.3%
Price Returns
2W
+0.1%
1M
-0.5%
3M
-42.0%
6M
-29.9%
12M
+164.3%
Technicals
52W High
$53.65
52W Low
$9.83
50d MA
$25.78
200d MA
$33.81
RSI (14)
45.50
ATR (14)
$1.26
Beta
5.16
Avg Volume
526K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$59.43
High
$97.00
Low
$46.00
Median
$55.00
Data updated apr 25, 2026 8:42pm
· Source: financialmodelingprep.com